title: Intervention effects of nedaplatin and cisplatin on proliferation and apoptosis of human tumour cells in vitro.
abstract: OBJECTIVE
  To study synergistic effects of nedaplatin and cisplatin on three human carcinoma cell lines (esophageal carcinoma cell line Eca-109, ovarian carcinoma Skov-3 and cervical carcinoma Hela).
  
  
  METHODS
  Inhibition effects were evaluated by MTT assay and cell apoptosis was detected by flow cytometry. In addition, changes of Ki-67, Bax and Bcl-2 at mRNA and protein levels were quantified by RT-PCR and Western blotting.
  
  
  RESULTS
  Growth inhibition in each cell lines was dose-dependent after exposure to nedaplatin or cisplatin alone. The interaction of the two drugs was synergistic at higher concentrations according to the median-effect principle. The inhibition rates with nedaplatin, cisplatin and combined treatment were 41.9±4.1%, 47.4±2.9%, 52.5±0.9%(Eca-109), 39.0±1.26%, 45.0±1.45% , 56.2±1.44% (Skov-3) and 44.8±2.11%, 46.9±0.99%, 56.6±1.83% (Hela) respectively, with increase in apoptosis. Compared with the nedaplatin or cisplatin alone treatment group, the combinative treatment group's Ki-67 and bcl-2 mRNA (protein) expression was decreased while that of Bax mRNA (protein) was increased.
  
  
  CONCLUSIONS
  Compared to the effects of nedaplatin or cisplatin alone at high concentrations, combination of nedaplatin and cisplatin at low concentrations proved to be much more effective for inhibition of proliferation and the induction of apoptosis in the Eca-109, Skov-3 and Hela cell lines.
authors.affiliation: Department of Oncology, Zhong-Da Hospital, Southeast University Clinical Medical School, Nanjing, China.
authors.forename: Xiang-Yu
authors.initials: XY
authors.lastname: Su
authors.forename: Hai-Tao
authors.initials: HT
authors.lastname: Yin
authors.forename: Su-Yi
authors.initials: SY
authors.lastname: Li
authors.forename: Xin-En
authors.initials: XE
authors.lastname: Huang
authors.forename: Hua-Yang
authors.initials: HY
authors.lastname: Tan
authors.forename: Hong-Yu
authors.initials: HY
authors.lastname: Dai
authors.forename: Fang-Fang
authors.initials: FF
authors.lastname: Shi
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D002277:Carcinoma / Q000188:drug therapy*; D049109:Cell Proliferation / Q000187:drug effects*; D002945:Cisplatin / Q000494:pharmacology*; D004357:Drug Synergism; D004938:Esophageal Neoplasms / Q000188:drug therapy*; D005260:Female; D006367:HeLa Cells; D006801:Humans; D020128:Inhibitory Concentration 50; D019394:Ki-67 Antigen / Q000235:genetics / Q000378:metabolism; D009944:Organoplatinum Compounds / Q000494:pharmacology*; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000235:genetics / Q000378:metabolism; D012333:RNA, Messenger / Q000378:metabolism; D051028:bcl-2-Associated X Protein / Q000235:genetics / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; C494826:BAX protein, human; D019394:Ki-67 Antigen; D009944:Organoplatinum Compounds; D019253:Proto-Oncogene Proteins c-bcl-2; D012333:RNA, Messenger; D051028:bcl-2-Associated X Protein; C053989:nedaplatin; D002945:Cisplatin